Trial Profile
A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity, and Pharmacokinetics of ND-L02-s0201 Injection, A Vitamin A-coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Subjects With Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs BMS-986263 (Primary)
- Indications Fibrosis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 28 Feb 2024 According to a RRD International media release, RRD International name has changed its name to RRD Biopharma Development.
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
- 20 Oct 2017 According to a Bristol-Myers Squibb media release, data will be presented at The Liver Meeting 2017.